Enzyme < Enzyme inhibitor < Enzymopathy

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 27.
[0-20] [0 - 20][0 - 27][20-26][20-40]

Ident.	Authors (with country if any)	Title
000588 (2009)	Serge Guerreiro [France] ; Aurélie Ponceau [France] ; Damien Toulorge [France] ; Elodie Martin [France] ; Daniel Alvarez-Fischer [France] ; Etienne C. Hirsch [France] ; Patrick P. Michel [France]	Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization
000795 (2008)	Margarete Zanardo Gomes [Brésil] ; Rita Raisman-Vozari [France] ; Elaine A. Del Bel [Brésil]	A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway
000880 (2007)	Alexandre Kreisler [France] ; Patrick Gele [France] ; Jean-Francois Wiart [France] ; Michel Lhermitte [France] ; Alain Destke [France] ; Régis Bordet [France]	Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease : Fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not
000B11 (2005)	Marina Mapelli [Italie] ; Lucia Massimiliano [Italie] ; Claudia Crovace [Italie, États-Unis] ; Markus A. Seeliger [États-Unis] ; Li-Huei Tsai [France] ; Laurent Meijer [France] ; Andrea Musacchio [Italie]	Mechanism of CDK5/p25 binding by CDK inhibitors
000C60 (2004)	N. Hamaue [Japon] ; M. Minami [Japon] ; M. Terado [Japon] ; M. Hirafuji [Japon] ; T. Endo [Japon] ; M. Machida [Japon] ; T. Hiroshige [Japon] ; A. Ogata [Japon] ; K. Tashiro [Japon] ; H. Saito [Japon] ; S. H. Parvez [France]	Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus
000D47 (2003)	J. G. Delcros [France] ; M. Baudy Floc'H [France] ; C. Prigent [France] ; Y. Arlot-Bonnemains [France]	Proteasome inhibitors as therapeutic agents: Current and future strategies
000D70 (2003)	Olivier Rascol [France] ; Pierre Payoux [France, Portugal] ; Fabienne Ory [France] ; Joaquim J. Ferreira [France] ; Christine Brefel-Courbon [France] ; Jean-Louis Montastruc [France]	Limitations of current Parkinson's disease therapy. Discussion
000E14 (2002)		Parkinson et mouvements anormaux
000E28 (2002)	A. Destee [France] ; R. Bordet [France]	Stimulation dopaminergique continue, stimulation dopaminergique pulsatile
000F10 (2002)	P. Volders [Belgique] ; J. Van Hove [Belgique] ; R. J. U. Lories [Belgique] ; Ph. Vandekerckhove [Belgique] ; G. Matthijs [Belgique] ; R. De Vos [Belgique] ; M. T. Vanier [France] ; M. F. Vincent [Belgique] ; R. Westhovens [Belgique] ; F. P. Luyten [Belgique]	Niemann-Pick disease type B: An unusual clinical presentation with multiple vertebral fractures
000F34 (2002)	A. Angles [France] ; H. Bagheri [France] ; S. Saivin [France] ; J. L. Montastruc [France]	Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease
000F42 (2002)	J. S. Schneider [États-Unis] ; M. Giardiniere [États-Unis] ; P. Morain [France]	Effects of the prolyl endopeptidase inhibitor S17092 on cognitive deficits in chronic low dose MPTP-treated monkeys
000F62 (2002)	Marion Blin [France] ; Wim E. Crusio [États-Unis] ; Tobias Hevor [France] ; Jean-Francois Cloix [France]	Chronic inhibition of glutamine synthetase is not associated with impairment of learning and memory in mice
001063 (2001)	Stéphanie Barc [France] ; Guylène Page [France] ; Laurence Barrier [France] ; Alain Piriou [France] ; Bernard Fauconneau [France]	Impairment of the neuronal dopamine transporter activity in MPP+-treated rat was not prevented by treatments with nitric oxide synthase or poly(ADP-ribose) polymerase inhibitors
001078 (2001)	S. Descombes [France] ; A. M. Bonnet [France] ; U. E. Gasser [Suisse] ; C. Thalamas [France] ; J. Dingemanse [Suisse] ; I. Arnulf [France] ; M. P. Bareille [France] ; Yves Agid [France] ; O. Rascol [France]	Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease
001111 (2000)	M. H. Marion [Royaume-Uni]	Traitement médicamenteux des complications motrices à un stade évolué de la maladie de Parkinson
001121 (2000)	P. Damier [France]	Quelles stratégies thérapeutiques sont à conseiller à la phase initiale de la maladie ? Les autres traitements
001175 (2000)	A. Boireau [France] ; P. Dubedat [France] ; F. Bordier [France] ; A. Imperato [France] ; S. Moussaoui [France]	The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP+ accumulation
001231 (2000)	C. Warren Olanow [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France]	Continuous dopamine-receptor stimulation in early Parkinson's disease
001331 (1999)	R. J. Ferrante [États-Unis] ; P. Hantraye [France] ; E. Brouillet [France] ; M. F. Beal [États-Unis]	Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase
001342 (1999)		Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patients

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/KwdEn.i -k "Enzyme inhibitor" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/KwdEn.i  \
                -Sk "Enzyme inhibitor" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Enzyme inhibitor
}}

---

This area was generated with Dilib version V0.6.29. Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024